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Summary 
 
Migraine is one of the most common neurological disorders. Its pathomechanism is only 
partially known and therapy is not always effective. In migraine, activation of trigeminal 
system plays an important role involving peptides/enzymes like calcitonin gene-related 
peptide (CGRP), neuronal nitric oxide synthase (nNOS) and calcium/calmodulin-dependent 
protein kinase II α (CaMKIIα) and glutamate and α7-nicotinic acetylcholine (α7-nACh) 
receptors. 
Kynurenic acid is an endogenous antagonist of the above mentioned receptors, but its poor 
ability to cross the blood-brain barrier limits its therapeutic potential, therefore in our 
experiments we investigated effect of its pro-drug, L-kynurenine (L-KYN) combined with 
probenecid (PROB) and two newly synthesized kynurenic acid amides (KYNAa1, KYNAa2) 
on kynurenic acid concentration of the central nervous system in rats and on morphological 
and behavioural changes induced by systemic administration of nitroglycerin (NTG), an 
animal model of migraine.  
Our results showed that kynurenic acid concentration in cervical part of spinal trigeminal 
nucleus pars caudalis (C1-C2) - where most of the trigeminal nociceptors convey - was 
significantly increased one hour after L-KYN-PROB. Moreover, KYNAa2 also enhanced 
kynurenic acid levels suggesting that this new derivative, at least partially, transforms to 
kynurenic acid resulting in a possible direct and indirect action in the central nervous system. 
The significant decrease of CGRP and increase of c-Fos, nNOS and CaMKIIα four hours after 
NTG treatment in C1-C2 measured by immunohistochemistry and Western blotting reflect the 
activation and sensitization of the trigeminal system. These changes were attenuated by the 
pre-treatment with L-KYN-PROB, KYNAa1 and in a dose-dependent manner with KYNAa2 
probably due to their effects on the target receptors of kynurenic acid located in the peripheral 
and central part of the trigeminal system. The NTG-induced lower ambulation distance 
demonstrated by Open Field Test may indicate pain condition in rats, which can not be 
observed after pre-treatment with KYNAa2. Furthermore, the KYNAa2 administration lowers 
the basic ambulation distance which can reflect its central effect. 
Our results suggest that by modulating the activation and sensitization of the trigeminal 
system in animals, kynurenic acid or its derivatives can be potential drug candidates in the 
treatment of headaches.  
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Introduction 
 
Migraine 
Migraine, an idiopathic neurological disorder belonging to the primary headache group in 
the classification of the International Headache Society, is characterised by spontaneous, 
recurrent headache attacks followed by symptom free intervals (Headache Classification 
Committee of the International Headache Society, 2013). The headache is moderate or severe, 
unilateral, throbbing and is associated with nausea or vomiting, photophobia, phonophobia, or 
sensitivity to other sensory stimuli (Headache Classification Committee of the International 
Headache Society, 2013). One attack lasts 4-72 hours and blocks the normal daily routine, as 
the normal physical activity exacerbates the pain (Headache Classification Committee of the 
International Headache Society, 2013). Migraine is often accompanied with allodynia, when 
non-nociceptive stimuli cause pain sensation, which suggests a sensitization process at the 
level of second- and third-order trigeminal neurones (Burstein et al., 2000).  
Migraine is very common, its prevalence is about 12% (Stovner and Andree, 2010). It peaks 
in the period which is most productive in life, and the attacks are relatively abundant, 
worsening the quality of life and making the patients disabled (Lipton et al., 2005). It is the 
seventh-highest specific cause of disability in the world (Vos et al., 2012) resulting in an 
immense direct and indirect economic deficit reaching up to €1,222 per-person a year in eight 
countries representing 55% of the European Union’s adult population (Linde et al., 2012).  
Several theories have been suggested regarding the pathophysiology of migraine, but none 
of them can explain the full spectrum of the disorder. According to the first, so-called 
vascular theory, migraine attacks are induced by the initial intracranial vasoconstriction which 
is followed by sudden, rebound vasodilatation (Graham and Wolff, 1938). This theory 
explains the throbbing quality of headache, the efficacy of vasoconstrictive agents such as 
ergotamine or triptans and the migraine inducing effects of vasodilator compounds such as 
nitroglycerin (NTG) or calcitonin gene-related peptide (CGRP). The neurogenic theory was 
introduced by Mike Moskowitz and coworkers, who presumed that onset of a migraine attack 
is related to the activation of the trigeminovascular system, which results in sterile, 
neurogenic inflammation in dura mater and in the consequential sensitization of primary 
trigeminal neurones and the activation of the central trigeminal nociceptive pathways (Buzzi 
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et al., 1995). Since vascular and neurogenic theories failed to explain all aspects of migraine, 
e.g. central symptoms like nausea, vomiting and sensitivity to light and sound, other theories 
were also suggested. 
Functional imaging studies have revealed activation of the dorsolateral pons and the dorsal 
midbrain including nucleus raphe dorsalis, nucleus raphe magnus, locus coeruleus and 
periaqueductal grey matter during a migraine attack (Weiller et al., 1995), which are 
components of the pain-modulatory pathways and are in functional relationship with the 
trigeminal system and can be associated with migraine pathogenesis (Fejes et al., 2011).  
Another phenomenon partially explaining numerous symptoms of migraine is the theory 
linked to the cortical spreading depression (Bhaskar et al., 2013), which is an intense but slow 
continuous spread of excitation across the cerebral cortex followed by depression (Leao, 
1944) and accompanied by slowly spreading cortical hypoperfusion as well (Olesen et al., 
1981). This phenomenon is considered to be the physiological analogue of migraine aura, 
which is confirmed by studies using functional brain imaging (Hadjikhani et al., 2001). 
Cortical spreading depression was also able to activate the trigeminovascular afferents 
(Moskowitz et al., 1993) and could increase the persistent blood flow and cause plasma 
protein extravasation in the dura mater (Bolay et al., 2002).  
Nevertheless, migraine is considered as a primarily genetically determined disease with a 
polygenic background (Pietrobon, 2007) and a large amount of candidate genes were 
implicated in migraine by genetic studies, but the mechanism, by which they actually 
participate in its pathophysiology, is still poorly understood (Bhaskar et al., 2013). A rare 
monogenic subtype of migraine is the familial hemiplegic migraine which causes attacks 
indistinguishable from the classical form and is associated with prominent aura symptoms 
(Pietrobon, 2007). The three most common mutations include the missense mutation of the 
P/Q-type calcium channel alpha l subunit gene (CACNAlA) on chromosome 19, the mutation 
in the ATP1A2 gene, which encodes a Na+–K+-ATPase and the mutation of a Na+ channel 
gene (SCN1A), all of which lead to an increase of glutamate level in synaptic cleft producing 
a hyperexcitable state in migraineurs (Pietrobon, 2007).  
One of the common points in these different pathomechanism theories is the activation of 
the trigeminal system during the attacks. The trigeminal system is responsible for most of the 
pain processing originating from the area of head (Carpenter and Sutin, 1983) and provides an 
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important pain-transmitting link from the cranial vasculature to the central nervous system 
(Edvinsson et al., 2012). The cell bodies of the pseudounipolar first-order trigeminal neurones 
are located in the trigeminal ganglion (Carpenter and Sutin, 1983) and contain numerous 
neurotransmitters such as glutamate, CGRP, substance-P, pituitary adenylate cyclase-
activating polypeptide and neurokinin A (Edvinsson, 2011), which are released both at the 
periphery and in the central nervous system during the activation of trigeminal system. 
Consequently, enhanced CGRP level was measured in venous blood sampled from the 
external jugular vein ipsilateral to the side of headache during the migraine attack (Goadsby et 
al., 1990), which induces cranial vasodilatation (Ho et al., 2010) and greatly contributes to the 
peripheral plasma extravasation and neurogenic inflammation (Edvinsson et al., 2012). The 
released inflammatory substances rapidly sensitize the trigeminal first-order neurones 
(Strassman et al., 1996) resulting in a throbbing head pain, which is aggravated by activities 
increasing intracranial pressure, for example pulsations of the arteries, physical exercise, 
bending down, coughing and sneezing (Burstein et al., 2000).  
The neurotransmitters released from the central terminals of the primary nociceptors 
activate the second-order neurones in the spinal trigeminal nucleus pars caudalis (TNC) 
located in the medullary part of the brain stem blending into the substantia gelatinosa of the 
first two cervical spinal segments (Carpenter and Sutin, 1983). Animal studies show that in 
response to activation induced by thermal, mechanical and chemical noxious stimulation as a 
marker, the c-Fos transcription factor increases in the neurones located in the area of spinal 
cord and TNC corresponding to the terminal fields of primary nociceptive afferent fibres and 
to the distribution of nociresponsive neurones (Harris, 1998). The main transmitter released 
from first-order trigeminal neurones is glutamate, which acts on its own ionotropic and 
metabotropic receptors located in the trigeminal system (Tallaksen-Greene et al., 1992). 
Continuous activation originating from the sensitized primary nociceptors induces plastic and 
long-term changes in the second-order neurones mainly through the glutamate receptors 
resulting in the central sensitization, which manifests clinically in cutaneous allodynia of 
scalp and face (Burstein et al., 2000), when the non-nociceptive stimuli including combing the 
hair, scalp tenderness, and wearing glasses and contact lenses cause pain and discomfort. 
Central sensitization has a clinical significance as well, since the efficacy of acute attack 
treatment with triptans is decreased after its development (Burstein et al., 2005). In these 
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plastic changes, calcium/calmodulin-dependent protein kinase II alpha (CaMKIIα) plays 
important role (Willis, 2001) interacting with N-methyl-D-aspartate (NMDA) glutamate 
receptors (Garry et al., 2003) similarly to the long-term potentiation process related to 
learning and memory (Sanhueza and Lisman, 2013). 
Despite the extensive experimental data regarding the pathomechanism of migraine, it is not 
clearly known how migraine attacks are triggered. Furthermore, the current preventive and 
attack therapies are sometimes only moderately effective and often poorly tolerated. Animal 
experimental models can help us to elucidate emerging questions and to develop new drugs.  
 
Nitroglycerin model of migraine headache 
NTG is a highly lipophilic organic nitrate, which has been used for decades in the therapy of 
angina pectoris and myocardial infarction (Chiariello et al., 1976). It readily crosses 
biological membranes, including the blood-brain barrier (Torfgard et al., 1989) and is 
converted to nitric oxide (NO) in the body mainly enzymatically (Harrison and Bates, 1993). 
Endogenously, NO is synthesized by nitric oxide synthases (NOSs) and is chemically 
identical to endothelium derived relaxing factor (Moncada et al., 1988). It activates 
cytoplasmic guanylate cyclases, causing an increase of intracellular guanosine 3,5'-
monophosphate and cytosolic calcium and resulting in vasodilatation (Axelsson et al., 1979). 
Furthermore, it is involved in inflammatory responses (Coleman, 2002), cell communication 
(Morris et al., 1992), non-adrenergic and non-cholinergic nerve activity (Toda and Okamura, 
1990), regulation of glutamate release in the spinal cord (Okuda et al., 2001), pain 
transmission (Meller and Gebhart, 1993) and development of hyperalgesia (Dolan et al., 
2000).  
One of the most common side-effects of NTG is headache (Ashina et al., 2000) due to 
vasodilatation induced by NO, which occurs immediately after its administration. However in 
most of the migraineurs, the immediate headache is followed by a delayed, typical migraine 
headache without aura 4–6 hours after infusing NTG, which can not be attributed to NO’s 
prompt vasodilator effect (Sicuteri et al., 1987; Di Clemente et al., 2009). This observation 
and the results of a pilot study showing that treatment with a NOS inhibitor attenuates 
spontaneous migraine headaches in 67% of subjects (Lassen et al., 1997), contributed to the 
implication of NO in migraine pathogenesis.  
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In addition to the migraine-like headache induced by systemic administration of NTG, 
which was critically evaluated by several independent groups, NTG evolves numerous 
changes, which can be observed during a regular migraine attack too. These properties make 
systemic administration of NTG to a reliable, reproducible, generally accepted and easy to use 
model of human migraine. NTG can trigger migraine with aura as well, during which 
activation in the primary visual area of the occipital cortex was demonstrated (Afridi et al., 
2005). NTG induced premonitory symptoms (yawning, tiredness, irritability, neck stiffness, 
frequency of urination, hunger and low mood) in migraineurs, who have usually these 
symptoms before spontaneous migraine attack (Afridi et al., 2004). Both during genuine 
migraine attack (Weiller et al., 1995) and after taking of NTG by migraine patients, 
significant activation in the dorsal rostral brain stem and dorsal lateral pons can be observed 
during the pain, which was ipsilateral to the site of headache (Afridi et al., 2005). In healthy 
subjects, sublingual NTG induced changes in evoked cortical responses (Di Clemente et al., 
2009), which are comparable to those found immediately before and during a regular 
migraine attack (Afra et al., 2000). 
Furthermore, NTG can sensitize the trigeminal system as well. In healthy subjects, 
sublingual NTG induced changes in trigeminal nociceptive blink reflex and pain thresholds, 
which are consequences of NO’s action on structures of the central nervous system (Di 
Clemente et al., 2009) and similar changes have been reported during migraine attacks and 
thought to reflect sensitization of neurones in TNC (Kaube et al., 2002). After oral 
administration of NTG, migraineurs without aura exhibited changes reflecting sensitization of 
second-order nociceptive neurones within the TNC, including a significant heat pain threshold 
reduction and an increment in the amplitude of laser evoked potentials during headache when 
the supraorbital zones were stimulated (de Tommaso et al., 2004), which were similar to those 
observed during spontaneous migraine attack (de Tommaso et al., 2002). A typical feature of 
sensitization of the pain pathways - a significant facilitation in temporal summation of pain at 
spinal level - can be observed in migraineurs after NTG administration (Woolf, 2007), which 
was significantly facilitated in migraineurs, who developed migraine after NTG (Perrotta et 
al., 2011).  
The migraine-provoking effect of NTG is further supported by the fact that numerous 
symptoms induced by NTG respond to acute and prophylactic medications known to have an 
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effect in genuine migraine. Sumatriptan reduced the NTG-induced headache and decreased 
the middle cerebral artery blood flow velocity in healthy volunteers (Fullerton et al., 1999). 
NTG-induced a more pronounced decrease of intracranial blood flow velocity in the middle 
cerebral artery in migraine patients, which disappeared one hour after zolmitriptan or 
sumatriptan administration (Thomaides et al., 2003). Similarly to spontaneous migraine attack 
(Goadsby et al., 1990), plasma CGRP concentration increased significantly during the 
migraine-like headache induced by sublingual administration of NTG in migraineurs without 
aura, while this change cannot be observed during immediate headache and in the subjects 
who do not have migraine-like headache (Juhasz et al., 2003). Interestingly, CGRP level 
showed significant positive correlations with migraine headache intensity (Juhasz et al., 2003) 
and sumatriptan was able to reduce the intensity of headache and the plasma concentration of 
CGRP (Juhasz et al., 2005). Prophylactically or ictally administered valproate – a well 
documented preventive drug in migraine treatment (Hering and Kuritzky, 1992) - was 
effective against the NTG-induced migraine-like headache in migraineurs without aura 
(Thomaides et al., 2008).  
Data from humans concerning NTG administration led to the hypothesis that NTG 
administration can function as an animal experimental model of migraine too, which was 
verified by experiments, since NTG can induce changes in animals similar to that of what 
happens in humans during the NTG-induced attack.  
Injection of NTG was able to trigger scratching head reactions, climbing cage, red ear and 
photophobia (Zhu et al., 2011; Markovics et al., 2012). Furthermore, NTG facilitated the face-
grooming behaviour - considered to reflect a specific nocifensive response - induced by 
CGRP, which was blocked by sumatriptan (Yao and Sessle, 2008). 
NTG administration induces dural and pial artery dilation (Gozalov et al., 2007) and leakage 
of plasma proteins from dural blood vessels (Reuter et al., 2001). It can evolve increased 
meningeal and cortical regional blood flow (Read et al., 1999; Greco et al., 2011; Markovics 
et al., 2012), which were attenuated by sumatriptan (Read et al., 1999) and which has been 
described in migraine and associated with migraine with aura (Olesen et al., 1981).  
NTG treatment can trigger release of transmitters present in the trigeminal system: in rats a 
significant decrease of the area innervated by CGRP-immunoreactive (IR) afferents in the 
cervical part of TNC (C1-C2) (Pardutz et al., 2002) and a marked increase of CGRP and 
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substance-P in plasma was detected, which latter was suppressed by local botulinum toxin 
type A injection, which is also effective in chronic migraineurs (Shao et al., 2013). Pituitary 
adenylate cyclase-activating polypeptide-38 and -27 immunoreactivity was increased 
significantly in the TNC of rats after NTG injection (Tuka et al., 2012), and similar tendency 
was observed in the plasma of migraineurs during the attack compared to the interictal period 
(Tuka et al., 2013).  
NTG treatment activates the trigeminal system reflected by changes of c-fos mRNA and c-
Fos protein expression - an anatomical marker of neuronal activity (Harris, 1998) - in the 
trigeminal ganglion and in the TNC (Tassorelli and Joseph, 1995; Markovics et al., 2012; 
Ramachandran et al., 2012), which were attenuated by pre-treatment with sumatriptan 
(Ramachandran et al., 2012).   
Behavioural, electrophysiological and morphological studies prove that NTG can cause the 
sensitization of the trigeminal system, which phenomenon is also present in migraineurs. A 
dose-dependent and prolonged NTG-induced thermal and mechanical allodynia was detected 
in mice, which were alleviated by sumatriptan (Bates et al., 2010). NTG caused a 
hyperalgesic response in the tail-flick test, which was attenuated by pre- or co-treatment with 
non-peptide CGRP receptor antagonist MK-8825 (Greco et al., 2013), inhibition of which 
receptor is effective in migraine too (Olesen et al., 2004). In rats, epidural NTG induces 
hyperalgesia at the level of the spinal cord (Masue et al., 1999), which was dose-dependently 
suppressed by epidural non-steroidal anti-inflammatory drugs e.g. indomethacin, diclofenac 
and ibuprofen (Masue et al., 1999) used generally against migraine headache (Silberstein, 
2000). Chronic intermittent administration of NTG to mice resulted in acute and chronic 
hyperalgesia, where the acute but not the chronic one was significantly reduced by 
sumatriptan, whereas both the acute and chronic hyperalgesia was significantly attenuated by 
topiramate which is effective in migraine prophylaxis (Pradhan et al., 2014). 
Electrophysiological results show, that infusions of NTG to cats increased the mean basal 
discharge rate of all second-order neurones in the TNC receiving sensory input from the 
superior sagittal sinus, a clear indication of a sensitization process, which can be decreased by 
iontophoretic application of the serotonin (1B/1D) receptor agonist eletriptan (Lambert et al., 
2002). 
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Increase in neuronal NOS- (nNOS) and CaMKIIα-IR neurones in the C1-C2 were detected 
four hours after systemic administration of NTG in male rats, suggesting the presence of self-
amplifying mechanisms in this area, possibly linked to a central sensitization process (Pardutz 
et al., 2000; 2007). The changes observed in expression of sensitization markers were 
attenuated by lysine acetylsalicylate and by NS398 (selective cyclooxygenase-2 inhibitor) 
(Pardutz et al., 2004; Varga et al., 2007; 2009). Interestingly, these alterations of nNOS and 
CaMKIIα immunoreactivity can not be observed in the thoracic dorsal horn (Pardutz et al., 
2000; 2007) showing a selective effect of NTG administration on the trigeminal system.  
To summarize, numerous experimental data in animals confirm that NTG is able to activate 
and sensitize the trigeminal system - phenomena also observed during migraine attacks - 
making NTG administration an appropriate animal experimental model of migraine headache.  
 
Kynurenines 
The kynurenine pathway is an endogenous metabolic route, which is responsible for the 
95% of tryptophan metabolism (Wolf, 1974) and takes place in the macrophages and 
microglial cells and in part in neurones (Guillemin et al., 2003; 2007). Its main end products 
are nicotinamid adenine dinucleotide and nicotinamid adenine dinucleotide phosphate (Beadle 
et al., 1947).  
Several metabolites of this pathway have neuroactive properties with toxic or protective 
effects. 3-hydroxykynurenine and 3-hydroxyanthranilic acid are neurotoxic through 
producing free radicals and elevating the oxidative stress level, causing neuronal damage and 
under pathological conditions, an increase in their concentration have been demonstrated 
(Fejes et al., 2011). Quinolinic acid has excitotoxic effect causing significant destruction of 
neurones after intrastriatal administration (Guidetti and Schwarcz, 1999) presumably through 
agonism on the NMDA receptor (Stone and Perkins, 1981) or by the stimulation of the release 
and inhibition of uptake of glutamate (Tavares et al., 2002). It also induces lipid peroxidation 
(Rios and Santamaria, 1991) and the production of reactive oxygen species (Behan et al., 
1999). Changes of its concentration in the cerebrospinal fluid have been demonstrated in 
various neurodegenerative disorders (Klivenyi et al., 2004). Xanthurenic acid is considered as 
a part of a detoxification process that reduces the concentration of 3-hydroxykynurenine 
(Gobaille et al., 2008). Its administration in high dosages to rats seems to induce a degree of 
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sedation and analgesia (Heyliger et al., 1998). Experimental data strongly indicate a 
physiological role for xanthurenic acid in synaptic signalling (Gobaille et al., 2008).  
L-kynurenine (L-KYN) itself is not a neuroactive compound, but it has a central role in the 
kynurenine pathway, since it is the precursor of kynurenic acid, which is the main 
neuroprotective end product of this metabolic route. Its protective effect is demonstrated by 
several experimental results, where kynurenic acid reduced brain damage induced by 
hypoxic-ischemia (Andine et al., 1988), reversed the contralateral turning caused by 
quinolinic acid-induced lesions of the nigrostriatal dopaminergic pathway (Miranda et al., 
1999) and induced neuroprotection in mouse cortical neuron cultures (Klein et al., 2013). This 
feature is probably related to various receptorial actions, like NMDA antagonism at 7.9 µM 
by attaching to its glycine-binding site (Kessler et al., 1989), inhibition of the α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors at high micromolar 
concentration (Prescott et al., 2006), the blockade of α7-nicotinic acetylcholine (α7-nACh) 
receptors in a non-competitive manner at low concentrations (30–100 nM) by binding to sites 
located in the N-terminal domain (Pereira et al., 2002) and the ability to agonise the G-
protein-coupled receptor-35 (GPR-35) at 7.4 µM concentration (Wang et al., 2006). Changes 
in its concentration in pathological circumstances were also described, namely it decreases in 
epilepsy, infantile spasm, Parkinson’s disease, multiple sclerosis, Huntington’s disease and 
Alzheimer’s disease and increases in viral infections (Klivenyi et al., 2004; Nemeth et al., 
2006) suggesting its role in pathomechanism of various neurological disorders. Furthermore, 
emerging evidence underlines that kynurenic acid can be crucial in nociception including 
migraine too. Its peripheral and central administration proved to be anti-nociceptive in animal 
experimental models of pain (Kristensen et al., 1993; Mecs et al., 2009) and enhancement of 
its concentration in the central nervous system attenuated the increase of NTG-induced nNOS 
immunoreactivity (Vamos et al., 2009). Based on these observations, manipulation of 
kynurenic acid levels in the nervous system could provide a therapeutic option in many 
neurological diseases especially in migraine. Unfortunately, this is rather restricted because it 
has only a very limited ability to cross the blood–brain barrier (Fukui et al., 1991). To resolve 
this issue, L-KYN and probenecid (PROB) are given together, since L-KYN crosses the 
blood-brain barrier easily (Fukui et al., 1991) and PROB inhibits the excretion of kynurenic 
acid from the brain resulting a dose-dependent and robust increase in the level of kynurenic 
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acid in the central nervous system (Vecsei et al., 1992). Furthermore, recent experimental 
results underline the importance of the application of various derivatives of kynurenic acid 
with a presumed better central nervous system penetration and similarity regarding their 
pharmacological effect (Knyihar-Csillik et al., 2008; Vamos et al., 2009; Marosi et al., 2010; 
Zadori et al., 2011b; Demeter et al., 2012; Gellert et al., 2012).  
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Aims 
 
The aims of our studies were to 
 
I. Determine the kynurenic acid concentration in the C1–C2 spinal cord segments of the 
rat, receiving most of the trigeminal nociceptive input, using high performance liquid 
chromatography (HPLC) either 60 minutes after intraperitoneal treatment with L-KYN 
combined with PROB, or 60 and 300 minutes after the administration of a newly 
synthesized kynurenic acid derivative.   
II. Examine the modulatory effect of the pre-treatment with L-KYN combined with PROB 
or the administration of two new kynurenic acid amides on the NTG-induced activation 
of primary trigeminal neurones by measuring the transmitter release from the central 
terminals indicated by CGRP expression in the C1-C2 using immunohistochemistry and 
Western blotting.  
III. Investigate the suspected dose-dependent influence of one of the two new kynurenic 
acid derivatives on the activation of second-order trigeminal neurones located in the C1-
C2 reflected by c-Fos immunohistochemistry. 
IV. Test the supposed effect of pre-treatment with L-KYN combined with PROB and with 
two new kynurenic acid amides on the NTG-induced sensitization of second-order 
trigeminal neurones reflected by the nNOS and CaMKIIα expression measured by 
immunohistochemistry and Western blotting in the same area. 
V. Study the potential modulatory effect of NTG administration on the behaviour of rats in 
Open Field Test and detect the modulatory effect of pre-treatment of one of the two new 
kynurenic acid amides on the NTG-induced changes.  
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Materials and Methods 
 
Animals 
The procedures utilized in this study followed the guidelines for the Use of Animals in 
Research of the International Association for the Study of Pain and the directives of the 
European Economic Community (86/609/ECC). They were approved by the Committee of 
Animal Research at the University of Szeged (I-74-12/2012) and the Scientific Ethics 
Committee for Animal Research of the Protection of Animals Advisory Board 
(XI./352/2012). One hundred and forty-four adult male Sprague-Dawley rats weighing 200-
250 g were used. The animals were maintained on a 12-h dark – 12-h light cycle under 
standard laboratory conditions, with tap water and regular rat chow available ad libitum. 
 
Drugs 
L-KYN and PROB were obtained from Sigma-Aldrich.  
The new kynurenic acid amides (Patent number #P0900281/PCT/HU2010/00050), N-(2-
N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride (KYNAa1) and 
N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride (KYNAa2) 
(Figure 1), were synthesized in the Department of Pharmaceutical Chemistry, University of 
Szeged with regard to the following structural properties: (i) the presence of a water-soluble 
side-chain, (ii) the inclusion of a new cationic centre, and (iii) side-chain substitution to 
facilitate brain penetration (Fulop et al., 2012). Coupling between kynurenic acid and 2-
dimethylaminoethylamine was achieved by using N,N’-diisopropylcarbodiimide in the 
presence of 1-hydroxybenzotriazole hydrate, yielding KYNAa1 (Fulop et al., 2012). 
KYNAa2, containing the tertiary nitrogen in pyrrole ring system, were prepared by reacting 
kynurenic acid with 2-pyrrolidinoethylamine (Fulop et al., 2012).  
NTG and its Placebo were obtained from Pohl-Boskamp.  
The dosages of drugs were chosen on the basis of earlier works (Vecsei et al., 1992; Pardutz 
et al., 2000; Vamos et al., 2009). 
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Figure 1. The structure of the new kynurenic acid amides, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-
2-carboxamide hydrochloride (KYNAa1) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride (KYNAa2).  
 
Drug administration 
For the HPLC measurements: The animals were divided into three groups. In the control 
group, the animals received only the intraperitoneal (i.p.) vehicle solution (physiological 
saline) as treatment (n=4), without drug. In the second group (n=4), the rats received an i.p. 
injection of L-KYN (300 mg/kg body weight (bw), diluted to 2 ml, pH 7.4) and PROB (200 
mg/kg bw, diluted to 1.5 ml, pH 7.4). In the third group (n=10), the rats were treated with an 
i.p. injection of 1 mmol/kg bw KYNAa2 (diluted to 2 ml, pH 7.4).  
For immunohistochemistry: The animals were divided into six groups. The animals of the 
control group (n=12) received only the i.p. vehicle solution (physiological saline) as pre-
treatment. The rats in the second group (n=12) received an i.p. injection of L-KYN (300 
mg/kg bw, diluted to 2 ml, pH 7.4) combined with PROB (200 mg/kg bw, diluted to 1.5 ml, 
pH 7.4). In the third group (n=12), the rats were injected intaperitoneally with the KYNAa1 (1 
mmol/kg bw, diluted to 2 ml, pH 7.4). In the remaining 3 groups (n=10 per group), the rats 
were pre-treated with an i.p. injection of KYNAa2 at dosages of 0.1, 0.5 and 1 mmol/kg bw, 
respectively (diluted to 2 ml, pH 7.4). One hour after the pre-treatment in each group, half of 
the animals (n=6 or 5) received an i.p. injection of NTG (10 mg/kg bw), while the other half 
of the rats (n=6 or 5) received an i.p. injection of the Placebo of NTG.  
For Western blotting: The animals were divided into two groups (n=10 per group). The 
animals in the control group received i.p. vehicle solution (physiological saline) only as pre-
treatment. In the second group, the rats were pre-treated with an i.p. injection of 1 mmol/kg 
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bw KYNAa2. The administration of Placebo and NTG was performed as described above, i.e. 
one hour after the pre-treatments.  
For the Open Field Test: The animals were separated into two groups (n=20 per group). In 
the control group, the animals received i.p. vehicle solution (physiological saline) as pre-
treatment, without drug. In the second group, the rats were pre-treated with an i.p. injection of 
KYNAa2 at the dose of 1 mmol/kg bw. The administration of Placebo and NTG was 
performed as described above. 
 
Kynurenic acid detection with HPLC 
Sampling and sample preparation: At determined time points following the i.p. injection (60 
minutes in the control and L-KYN-PROB groups and 60 and 300 minutes in the KYNAa2 
group), the rats were deeply anesthetized with chloral hydrate (0.4 g/kg bw, Sigma-Aldrich) 
and transcardially perfused with 100 ml phosphate-buffered saline (PBS, 0.1 M, pH 7.4) for 5 
minutes. The C1-C2 segments were removed and stored at −70 °C until analysis. Then the 
samples were weighed and sonicated in an ice-cooled solution (250 µl) comprising perchloric 
acid (2.5% w/w, Scharlau), internal standard (3-nitro-L-tyrosine, 2 µM, Sigma-Aldrich,) and 
distilled water for 1.5 minutes in an Eppendorf tube. The content of the Eppendorf tube was 
centrifuged at 12,000 rpm for 10 minutes at 4 °C. From the supernatant 100 µl was transferred 
to a test vial.  
Chromatographic conditions: The kynurenic acid concentrations of the samples were 
quantified based on the slightly modified method of Herve and colleagues (Herve et al., 
1996), with an Agilent 1100 HPLC system (Agilent Technologies). The system was equipped 
with a fluorescent and an UV detector. The former was applied for the determination of 
kynurenic acid and the latter for the determination of the internal standard. Chromatographic 
separations were performed on an Onyx Monolithic C18 column, 100 mm x 4.6 mm I.D. 
(Phenomenex Inc.) after passage through a Hypersil ODS pre-column, 20 x 2.1 mm I.D., 5 
µm particle size (Agilent Technologies) with a mobile phase composition of 0.2 M zinc 
acetate (Sigma-Aldrich)/acetonitrile (Scharlau) = 95/5 (v/v), the pH of which was adjusted to 
6.2 with acetic acid (VWR International), applying isocratic elution. The flow rate and the 
injection volume were 1.5 ml/minute and 50 µl, respectively. The fluorescent detector was set 
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at excitation and emission wavelengths of 344 and 398 nm. The UV detector was set at 365 
nm wavelength. The retention time of kynurenic acid was about 6 minutes. 
HPLC method validation: Calibration curve and linearity - Calibrants were prepared at 6 
different concentration levels, from 1 to 100 nM and 0.5 to 5 µM for kynurenic acid and the 
internal standard, respectively. Three parallel injections of each solution were made under the 
chromatographic conditions described above. The peak area responses were plotted against 
the corresponding concentration, and the linear regression computations were carried out by 
the least square method with the freely available R program (R Foundation for Statistical 
Computing, R Development Core Team). Very good linearity was observed throughout the 
investigated concentration ranges for kynurenic acid and the internal standard when either 
fluorescence or UV detection was applied. Selectivity - The selectivity of the method was 
checked by comparing the chromatograms of kynurenic acid and the internal standard for a 
blank central nervous system sample and those for a spiked sample. All compounds could be 
detected in their own selected chromatograms without any significant interference. LOD and 
LLOQ - Limit of detection (LOD) and lower limit of quantitation (LLOQ) was determined via 
signal-to-noise ratio with threshold 3, according to the ICH guidelines (Validation of 
Analytical Procedures: Text and Methodology Q2 (R1), International Conference on 
Harmonization). The LOD was 0.4 nM, while the LLOQ was 1 nM for kynurenic acid, 
respectively. Precision - Replicate HPLC analysis showed that the relative standard deviation 
was ≤ 3.1% for the concentration and ≤ 0.1% for the retention time. Recovery - The relative 
recoveries were estimated by measuring spiked samples of kynurenic acid at 2 different 
concentrations with 3 replicates of each. No significant difference was observed for the lower 
and higher concentrations. The recoveries ranged from 82 to 92% for kynurenic acid. 
 
Immunohistochemistry 
Histological procedure: Four hours after treatment with Placebo or NTG, the rats, 
anaesthetized with chloral hydrate as described above, were perfused transcardially with 100 
ml PBS, followed by 500 ml 4% paraformaldehyde in PBS and the C1-C2 segment of the 
cervical spinal cord was removed. After overnight postfixation in the same fixative and 
cryoprotection (10% sucrose for 2 h, 20% sucrose until the blocks sank, and 30% sucrose 
overnight), 30 µm cryostat sections were cut, serially collected in 18 wells containing cold 
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PBS, where each well received sections at a 0.54-mm distance throughout the rostrocaudal 
extent of the C1-C2 segments and treated as free-floating sections. After suppression of the 
endogenous peroxidase activity with 0.3% H2O2 in PBS for 30 minutes and several rinses in 
PBS containing 1% Triton X-100 (PBST, VWR International), sections were incubated in 
PBST containing (i) rabbit anti-rat CGRP polyclonal antibody (Sigma-Aldrich, C-8198, 
dilution: 1:20,000, incubation: overnight at room temperature) or (ii) rabbit anti-rat c-Fos (H-
125) polyclonal antibody (Santa Cruz Biotechnology, sc-7202, dilution: 1:1,000, incubation: 
overnight at room temperature) or (iii) rabbit anti-rat nNOS polyclonal antibody 
(EuroProxima, 2263B220-1, dilution: 1:5,000, incubation: two nights at 4 °C) or (iv) mouse 
anti-rat CaMKIIα monoclonal antibody (Sigma-Aldrich, C-265, dilution: 1:2,000, incubation: 
four nights at 4 °C). The immunohistochemical reaction was visualized by using Vectastain 
Elite avidin-biotin kits (Vector Laboratories; PK6101 for c-Fos, nNOS and CGRP; PK6102 
for CaMKIIα). The sections were incubated at room temperature for 2 hours in PBST 
containing goat anti-rabbit or horse anti-mouse biotinylated secondary antibody, respectively. 
After several rinses in PBST, and incubation at room temperature for 2 hours in PBST 
containing avidin and biotinylated horseradish peroxidase, the sections were stained with 
3,3’-diaminobenzidine (Sigma-Aldrich) intensified with nickel ammonium sulphate (VWR 
International). The specificity of the immune reactions was checked by omitting the primary 
antiserum. 
Data evaluation: All evaluations were performed by an observer blind to the experimental 
groups. The area covered by CGRP-IR fibres in laminae I and II of the cervical dorsal horns 
was determined by video imaging, using Image Pro Plus 6.2® image analysis software 
(Media Cybernetics). Photomicrographs of sections were taken under the 4x objective of a 
Nikon Optiphot-2 light microscope fitted with an Olympus DP70 CCD camera (Olympus 
Corporation) and transmitted to the frame grabber, which converted the image into a digital 
matrix of 1600 x 1200 pixels. After image acquisition, the laminae I-II in dorsal horn were 
determined manually as area of interest by means of The Rat Brain in Stereotaxic Coordinates 
Atlas (Paxinos and Watson, 2007) and a threshold grey level was established with the Image 
Pro Plus 6.2® image analysis software in order to detect IR fibres in the digitalized 
microscopic image. To avoid the subjective bias of manual thresholding, the threshold was 
determined on the basis of the density histogram displayed by the program. It was set on the 
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point where the flat part of the histogram started to rise steeply. The program expressed the 
area innervated by the IR fibres as the number of pixels with densities above the threshold. 
For the calibration, we measured formations with known area. The area covered by IR fibres 
per dorsal horn was calculated as the multiplication of the average number of pixels for the 
individual dorsal horn and the area of one pixel.  
The c-Fos-, nNOS- and CaMKIIα-IR cells were counted by an observer blinded to the 
procedure under the 10x objective of a Nikon Optiphot-2 light microscope (Nikon 
Instruments) in laminae I-II of the C1-C2. The c-Fos-positive neurones were scored as those 
with obvious specific nuclear staining; the nNOS-IR neurones as those exhibiting cytoplasmic 
and dendritic staining; and the CaMKIIα-labelled cells with a clearly increased 
immunoreactivity relative to the background. In three different series of sections in each 
animal, the number of IR neurones per section was calculated, i.e. the numbers of 
immunopositive neurones present on the two dorsal horns were summed. Thereafter, the 
results on the individual sections were averaged for each animal.  
Photomicrographs were taken under 4x objective of Nikon Optiphot-2 light microscope 
fitted with an Olympus DP70 CCD camera or under the 40x and 63x objective of a Zeiss 
Axio Imager M2 Upright Microscope (Carl Zeiss MicroImaging) fitted with an AxioCam 
MRc camera (Carl Zeiss MicroImaging) and Adobe Photoshop CS2 9.0 graphics program 
was used to create the artworks.  
 
Western blotting 
Sampling and sample preparation: In both groups four hours after the NTG or Placebo 
injections, the rats were deeply anaesthetized with chloral hydrate as described above, 
perfused transcardially with 100 ml ice cold PBS and the dorsal horn of C1-C2 segment was 
removed. Until measurements, the samples were stored at −70 °C. The C1-C2 segments were 
sonicated in ice cold lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 0.1% igepal, 
0.1% cholic acid, 2 µg/ml leupeptin, 2 mM phenylmethylsulphonyl fluoride, 1 µg/ml 
pepstatin, 2 mM EDTA and 0.1% sodium dodecyl sulphate (all chemicals were from Sigma-
Aldrich). The lysates were cleared from cellular debris by centrifugation at 12,000 rpm for 10 
minutes at 4 °C and supernatants were aliquoted and stored at -20 °C. Protein concentration 
was measured according to BCA protein assay method with BCA Protein Assay Kit 
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(Novagen) using bovine serum albumin as a standard. Samples were cooled on ice during the 
whole procedure. Prior to loading, each sample was mixed with sample buffer, and 
denaturated by boiling for 3 minutes. Equal amounts of protein samples (20 µg/lane) were 
separated by standard SDS polyacrylamide gel electrophoresis on 10% (for nNOS and β-
actin) and 15% (for CGRP) Tris–Glycine gel and electrotransferred onto Amersham Hybond-
ECL nitrocellulose membrane (0.45 and 0.2 µm pore size selectively, GE Healthcare). The 
Page Ruler Prestained Protein Ladder (Fermentas, 10-170 kDa) was used to determine 
approximate molecular weights. Following the transfer, membranes were blocked for one 
hour at room temperature in Tris-buffered saline containing Tween 20 (TBST, MP 
Biomedicals) and 5% non fat dry milk powder and incubated in TBST containing 1% non fat 
dry milk and (i) rabbit anti-rat CGRP polyclonal antibody (Sigma-Aldrich, C-8198, dilution: 
1:2,000, incubation: overnight at room temperature) or (ii) mouse anti-rat nNOS monoclonal 
antibody (BD Biosciences, 610308, dilution: 1:2,500, incubation: overnight at room 
temperature) or (iii) mouse anti-rat β-actin monoclonal antibody (Calbiochem, CP01, dilution: 
1:10,000, incubation: overnight at room temperature). Next day after several rinses, 
membranes were incubated in TBST containing 1% non fat dry milk and horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (Santa Cruz 
Biotechnology; sc-2030 and sc-2031) for two hours at room temperature. Protein bands were 
visualized after incubation of membranes with the SuperSignal West Pico Chemiluminescent 
Substrate (Pierce) using Carestream Kodak BioMax Light film (Kodak).  
Data evaluation: For densitometric analyses, films were scanned and quantified using Java 
ImageJ 1.47v analysis software (National Institutes of Health). The results were normalized to 
the absolute control animals. β-actin served as a control to ensure loading of equivalent 
amounts of sample proteins.  
 
Open Field Test 
Before the Open Field Test, animals were habituated in the dimly lit, quiet test room for at 
least 30 minutes. The experiments were performed between 11 a.m. and 4 p.m. during the 
light cycle of rats. To avoid misinterpretation related to the acute cardiovascular effects of 
NTG and in parallel with earlier studies showing delayed behavioural alterations after 
systemic NTG in mice (Markovics et al., 2012), we tested the rats three hours and forty 
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minutes after the NTG or Placebo injections. The animals were placed in the Open Field box 
(48x48x40 cm, Experimetria Ltd.) and ambulation time, ambulation distance, local time and 
the number of rearings were registered for 15 minutes, and were evaluated using the Conducta 
1.0 behaviour analysis program (Experimetria Ltd.). The rats did not receive any food or 
water during the observation period. The test box was cleaned and decontaminated after each 
animal. 
 
Statistical analysis 
Statistical analysis of the measurement data was carried out with IBM SPSS Statistics 
software (Version 20, IBM), using one-way analysis of variance followed by the Tukey, 
Schaffe or Tamhane post hoc test (except for the data of HPLC analyses), depending on the 
variances of the data, with p<0.05 taken as statistically significant. Group values are reported 
as means ± standard error of the mean (S.E.M.). The independent Student t-test was used to 
analyse the results of HPLC measurements to compare the vehicle-treated and the L-KYN-
PROB-treated groups. While to compare the vehicle-treated and the KYNAa2-treated groups, 
the non-parametric Kruskal-Wallis test was applied for group comparisons followed by 
Mann-Whitney U test for post hoc analysis, with p<0.05 taken as statistically significant, 
where the group values are reported as median and interquartile range. 
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Results 
 
Kynurenic acid detection with HPLC 
The HPLC measurements of kynurenic acid concentration clearly indicated a robust, 
statistically significant increase in kynurenic acid level in the C1-C2 one hour after 
administration of L-KYN combined with PROB (2967,42±395.76 pmol/g wet weight) as 
compared with control group (11.76±1.67 pmol/g wet weight) (***p<0.001) (Figure 2). 
 
 
 
 
 
 
Figure 2. Histogram showing the kynurenic acid level in the C1-C2 spinal cord segments after vehicle or L-
KYN combined with PROB treatment (means ± S.E.M., n = 4 per group). L-KYN-PROB significantly increased 
the kynurenic acid level in the C1–C2 segments as compared with the control group (***p<0.001). 
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The HPLC measurements showed a significant (*p<0.05), more than two-fold increase in 
kynurenic acid level in the C1-C2 60 minutes after 1 mmol/kg bw KYNAa2 administration 
(25.38 pmol/g wet weight, interquartile range: 23.26-40.80 pmol/g wet weight) compared to 
vehicle treated samples (11.48 pmol/g wet weight, interquartile range: 8.85-15.00 pmol/g wet 
weight) (Table 1), while the concentration of kynurenic acid decreased to baseline at 300 
minutes (9.02 pmol/g wet weight, interquartile range: 6.43-30.92 pmol/g wet weight) (Table 
1). Although, it requires a different validation method, we screened the kynurenic acid 
concentration on the blood samples too. Preliminary results suggest a robust increase 
(approximately 50x) in the peripheral kynurenic acid levels reaching µmolar concentrations 
(data not shown). 
 
Table 1 - Results of HPLC measurements from the C1-C2 at different time points after 
KYNAa2 treatment 
Groups Kynurenic acid concentrations (pmol/g wet weight; median 
and interquartile range) 
Control (saline) 
(n=4) 60 min 11.48 (8.85-15.00) 
60 min 
(n=5) 25.38 (23.26-40.80)* 
1 mmol/kg 
bodyweight 
KYNAa2 
(n=10) 
300 min 
(n=5) 9.02 (6.43-30.92) 
*p<0.05 
 
 
Immunohistochemistry 
The transverse sections of the C1-C2 demonstrated abundant CGRP-positive fibres, and c-
Fos-, nNOS- and CaMKIIα-IR neurones in the superficial layers (laminae I-II) of the dorsal 
horns. The area covered by IR fibres and the number of IR cells did not differ significantly 
between sections located at the various levels along the rostrocaudal axis or between the right 
and left dorsal horns of the cervical segments.  
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Figure 3. Representative photos of sections from the C1-C2 segments of the rat after CGRP 
immunohistochemistry. (I) CGRP immunoreactivity in the C1-C2 in control (a, b), L-KYN-PROB-pre-treated 
(c, d), KYNAa1-pre-treated (e, f), and KYNAa2-pre-treated (g, h) rats after Placebo (a, c, e, g) or NTG (b, d, f, 
h) injections. (II) CGRP-IR fibres and buttons under 40x objective (a, b) and under 63x objective (c, d) in 
Placebo (a, c) and NTG-treated (b, d) rats of the controls. In the control group (I/a, b and II), the IR staining of 
the CGRP fibres is decreased after the NTG injection (I/b, II/b, d) as compared with the Placebo-treated animals 
(I/a, II/a, b). After L-KYN-PROB (I/c, d) or 1 mmol/kg bw KYNAa1 (I/e, f) or 1 mmol/kg bw KYNAa2 (I/g, h) 
pre-treatment, the changes otherwise induced by NTG cannot be observed (I/d, f, h) compared to the animals 
treated with Placebo (I/c, e, g). Scale bar = 50 µm. 
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Figure 4. Histogram showing the mean area in µm2 covered by CGRP-IR fibres in superficial laminae I and II of 
the C1-C2 in the six animal groups after Placebo (white bars) or NTG (grey bars) (means ± S.E.M., n = 6 or 5 
per subgroup). In the control group, NTG injection significantly decreased the mean area covered by CGRP-IR 
fibres in the C1-C2 as compared with the Placebo-treated animals (**p<0.01). The combined pre-treatment with 
L-KYN-PROB and KYNAa1 (1mmol/kg bw) attenuated the NTG-induced changes. The significant difference 
between Placebo and NTG treated animals also appeared in the group pre-treated with 0.1 mmol/kg bw 
KYNAa2 (*p<0.05), but this phenomenon disappeared in the groups pre-treated with 0.5 and 1 mmol/kg bw 
KYNAa2. The effects of various pre-treatments are also reflected by the significant differences between the 
values of the NTG groups (#p<0.05; ##p<0.01; ###p<0.001). 
 
 
In the control group, reduced CGRP staining can be observed in laminae I-II of the C1-C2 
segments after NTG treatment compared to Placebo treated rats (Figure 3). This decrease is 
reflected in area covered by CGRP as well, i.e. significant difference can be measured in 
NTG-treated rats as compared with Placebo-treated animals (**p<0.01; Figure 4).  
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Figure 5. Representative photos of c-Fos immunoreactivity in the C1-C2 segments of the rat. In the control 
group (a, b), more c-Fos-IR cells can be observed in the superficial laminae of the C1-C2 after NTG injection (b) 
as compared with the Placebo-treated animals (a). This NTG-induced change is not detected after 1 mmol/kg bw 
KYNAa2 pre-treatment (c, d). The black arrow in “b” indicates a c-Fos-positive cell. Scale bar: 100 µm 
 
 
 
Figure 6. The mean number of c-Fos-IR neurones (means ± S.E.M., n = 6 or 5 per subgroup). NTG injection 
significantly increased the mean number of c-Fos-IR cells in the C1-C2 in the control group as compared with 
the Placebo-treated rats (***p<0.001), which persisted after a pre-treatment with low dosage of KYNAa2 (0.1 
mmol/kg bw) (***p<0.001) and disappeared when the dosage of KYNAa2 was higher (0.5 mmol/kg and 1 
mmol/kg bw). We could not detect significant difference between NTG-treated rats of control group and of 
group receiving 0.1 mmol/kg bw KYNAa2, while there was significant difference between NTG-treated animals 
of control group and of groups pre-treated with 0.5 and 1 mmol/kg bw dose of KYNAa2 (##p<0.01; 
###p<0.001). 
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In the control group, increased c-Fos, nNOS and CaMKIIα immunoreactivity (Figures 5, 7, 
9) can be observed in the superficial layers of the C1-C2 after NTG treatment compared to 
Placebo. The differences in the numbers of IR neurones proved to be statistically significant 
for all three immunostainings (***p<0.001; Figures 6, 8, 10).  
 
 
 
 
 
Figure 7. Representative photos of nNOS-stained neurones in the C1-C2 of the rat. In the control group (a, b), 
an increased nNOS immunoreactivity can be observed in the superficial laminae of the C1-C2 after NTG 
injection (b) as compared with the Placebo-treated animals (a). In the group pre-treated with 1 mmol/kg bw 
KYNAa2 (c, d), the NTG-induced change can not be seen. The black arrow on photo (b) points to a nNOS-IR 
neurone. Scale bar: 100 µm 
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Figure 8. The average number of nNOS-IR cells (means ± S.E.M., n = 6 or 5 per subgroup). NTG injection 
significantly enhanced the mean number of nNOS-IR neurones in the C1-C2 in the controls as compared with 
the rodents treated with Placebo (***p<0.001). This significant increase was still present after pre-treatment with 
a low dosage of KYNAa2 (0.1 mmol/kg bw) (***p<0.001), while it disappeared in groups pre-treated with 
higher dosages of KYNAa2 (0.5 and 1 mmol/kg bw). The effects of different pre-treatments are also reflected by 
the significant differences between the values of the NTG groups (##p<0.01; ###p<0.001). 
 
 
 
Both L-KYN-PROB and KYNAa1 pre-treatment successfully attenuated the decrease in 
CGRP and increase in CaMKIIα immunopositivity (Figures 3, 4, 9, 10). The pre-treatment 
with KYNAa2 affected dose-dependently the NTG-induced changes in the immunoreactivity 
of all studied markers (Figures 3-10).   
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Figure 9. Typical photos showing CaMKIIα-IR cells in the C1-C2 segments of the rat. (I) CaMKIIα 
immunopositivity in the C1-C2 in control (a, b), L-KYN-PROB-pre-treated (c, d), KYNAa1-pre-treated (e, f) 
and KYNAa2-pre-treated (g, h) rats after Placebo (a, c, e, g) or NTG (b, d, f, h) injections. (II) CaMKIIα-IR 
neurones under 40x objective (a, b) and under 63x objective (c, d) in Placebo (a, c) and NTG-treated (b, d) 
animals of the controls. Increased CaMKIIα staining can be observed in the superficial laminae of the C1-C2 in 
the control group (I/a, b and II) after NTG injection (I/b, II/b, d) as compared with the Placebo-treated animals 
(I/a, II/a, c). In the groups pre-treated with L-KYN-PROB (I/c, d), 1 mmol/kg bw KYNAa1 (I/e, f) and 1 
mmol/kg bw KYNAa2 (I/g, h), this enhancement is not visible after NTG injection (I/d, f, h) relative to the 
Placebo treatment (I/c, e, g). The black arrow in “I/b” points to a CaMKIIα-immunopositive neurone. Scale bar: 
50 µm 
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Figure 10. Histogram showing the mean number of CaMKIIα-IR cells in the C1-C2 in the six groups after 
Placebo (white bars) or NTG (grey bars) injections (means ± S.E.M., n = 6 or 5 per subgroup). There was a 
significant increase in the CaMKIIα-IR cells after the NTG injection in the control group (***p<0.001) and in 
the group pre-treated with the lowest dosage of KYNAa2 (0.1 mmol/kg bw) (*p<0.05). However, this 
enhancement did not appear in the L-KYN-PROB-pre-treated and the 1 mmol/kg bw KYNAa1-pre-treated 
animals and in the rats pre-treated with the higher dosages of KYNAa2 (0.5 and 1 mmol/kg bw). The effects of 
different pre-treatments are also reflected by the significant differences between the values of the NTG groups 
(#p<0.05; ###p<0.001). 
 
 
Western blotting 
Western blotting analysis of the C1-C2 region confirmed the results obtained by CGRP and 
nNOS immunohistochemistry. A band characteristic of the CGRP peptide was identified at 15 
kDa and nNOS protein was identified at 155 kDa (Figure 11). Densitometric analyses 
confirmed the immunohistochemical results, since the CGRP bands were significantly 
decreased (*p<0.05) and nNOS bands were significantly enhanced (***p<0.001) in dorsal 
horn of C1-C2 segments after NTG administration as compared with the Placebo-treated 
animals (Figure 11). This effect of NTG on CGRP and nNOS was attenuated by pre-treatment 
with 1 mmol/kg bw KYNAa2 (Figure 11).  
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Figure 11. Western blotting of CGRP and nNOS in the C1–C2 segments of the spinal cord (means ± S.E.M., n = 
5 per subgroup). Density of CGRP band decreased (a, b) and density of nNOS band increased (c, d) significantly 
after NTG administration compared to the Placebo in the control group (*p<0.05; ***p<0.001), which was 
attenuated by pre-treatment with 1 mmol/kg bw KYNAa2 
 
 
 
Open Field Test 
Treatment with NTG significantly decreased the ambulation distance of the animals 
compared to Placebo-treated rats (*p<0.05; Figure 12). Pre-treatment with 1 mmol/kg bw 
KYNAa2 attenuated this difference, but a tendency for a lower basic ambulation distance was 
observed after KYNAa2 pre-treatment (Figure 12). There were no significant changes in 
ambulation time, local time or in the number of rearing between the subgroups (data not 
shown).  
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Figure 12. Diagram showing the results of Open Field Test (means ± S.E.M., n = 10 per subgroup). In the 
control group, treatment with NTG decreased the ambulation distance significantly compared to Placebo-treated 
rats (*p<0.05). Pre-treatment with 1 mmol/kg bw KYNAa2 attenuated this effect of NTG, however, a tendency 
for a lower basic ambulation distance can be observed in KYNAa2 group as compared with Placebo treated rats 
of control group as well.  
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Discussion 
 
Kynurenic acid concentrations in the C1-C2 
The HPLC data obtained after L-KYN-PROB show a robust increase of kynurenic acid 
concentration in the C1-C2, which corresponds to previous findings (Vecsei et al., 1992) and 
supported by further studies (Chauvel et al., 2013). Kynurenic acid has a poor blood-brain 
barrier penetrance (Fukui et al., 1991), but administration of its precursor, L-KYN increases 
kynurenic acid concentration in the central nervous system dose-dependently. In experimental 
conditions, this effect of L-KYN can be enhanced with the co-administration of PROB by 
blocking the excretion of kynurenic acid, by inhibiting the organic acid transporters 
(Cunningham et al., 1981), which are involved in the transport of kynurenic acid from brain 
through the blood-brain barrier (Colin-Gonzalez and Santamaria, 2013). 
Using of kynurenic acid derivatives with a presumed better blood-brain barrier penetrance is 
an alternative option to increase the kynurenic acid concentration or mimic its effect. After the 
systemic administration KYNAa2, we witnessed a significant increase in the level of 
kynurenic acid in the C1-C2, suggesting that KYNAa2 is transformed at least partially to 
kynurenic acid. Similarly, partial transformation of KYNAa1 to kynurenic acid has been 
described after i.p. administration in serum of mice, parallel to which robust enhancement of 
KYNAa1 can be observed as well (Zadori et al., 2011a). Thus, central nervous effects of 
kynurenic acid derivatives might be related both to their direct action and to indirect influence 
via forming kynurenic acid. 
 
Activation of primary trigeminal neurones 
CGRP is an essential transmitter in the primary nociceptors and several lines of evidence 
prove its importance in migraine pathogenesis (Durham, 2006). 
Systemic NTG was able to reduce the CGRP content of the C1-C2, which is in the line with 
earlier experiments (Pardutz et al., 2002). NO released from NTG stimulates the first-order 
trigeminal nociceptors resulting in transmitter release from the central terminals of Aδ and C 
fibres targeting the second-order trigeminal nerve cells. This phenomenon was already 
described after the activation of primary trigeminal neurones (Zhang et al., 1994) and 
increased release or turnover of CGRP was reported at the level of the spinal cord in various 
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pain models (Sluka et al., 1992; Garry et al., 2000). Moreover in another model of trigeminal 
activation, morphological alterations were observed at the level of the distal terminals located 
in the dura mater suggesting transmitter release after the electrical stimulation of the 
trigeminal ganglion (Knyihar-Csillik et al., 2000). In earlier studies, it was also proven that 
the size of the CGRP-positive buttons is smaller in the C1-C2 after NTG, which also 
suggestive for transmitter release (Pardutz et al., 2002). These animal experimental results can 
be paralleled by the observations showing increased CGRP concentration in the jugular vein 
of migraineurs during the attack (Goadsby et al., 1990). Interestingly, the effect of NTG 
seems to be selective to the trigeminal system, since we did not observe any changes at the 
level of the thoracic spinal cord (Pardutz et al., 2002).  
Our results indicate that L-KYN-PROB, KYNAa1 and in a dose-dependent manner 
KYNAa2 can mitigate the CGRP decrease in the trigeminal system caused by systemic NTG. 
Attenuation of CGRP release from the first-order trigeminal nociceptors suggest that 
kynurenic acid and its derivatives have a marked peripheral effect probably by inhibition of 
receptors involved in nociception located in the trigeminal system. This is also supported by 
the observation that kynurenic acid is able to reduce allodynia when administered topically in 
the joints (Mecs et al., 2009) and to decrease the pain sensitivity in both the tail-flick and the 
hot-plate tests after its intraperitoneal injection in rats (Heyliger et al., 1998). Moreover, the 
systemic administration of 5,7-dichlorokynurenic acid, a kynurenic acid derivative with 
limited central access, dose-dependently inhibited the nocifensive behaviour evoked by 
formalin-induced tissue injury and inflammation in Phase II. 5,7-Dichlorokynurenic acid was 
also effective in two models of neuropathic pain, where it reversed cold allodynia in the 
chronic constriction injury model, and tactile allodynia in animals subjected to spinal nerve 
ligation (Christoph et al., 2005).  
Glutamate receptors can be found on the peripheral arm of the trigeminal system (Watanabe 
et al., 1994; Quartu et al., 2002) and their inhibition mitigates CGRP release (Garry et al., 
2000). α7-nACh receptors are also present on the soma of primary trigeminal neurones (Liu et 
al., 1998) and glutamate release (Carpenedo et al., 2001) and CGRP induced facial 
vasodilation (Just et al., 2005) are reduced after their inhibition. Expression of GPR-35 can be 
observed within the sensory ganglia and spinal cord, activation of which can modulate 
nociceptive signalling (Ohshiro et al., 2008). 
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The blockade of the CGRP release at the level of first-order trigeminal nociceptors indicates 
that kynurenic acid and its derivatives are able to influence the pain processing on the 
periphery.  
 
Activation of second-order trigeminal neurones 
The NO-induced c-Fos expression observed at the level of the C1-C2 reflecting an 
activation of the second-order trigeminal nerve cells was already observed in earlier studies 
(Tassorelli and Joseph, 1995) and appears to be selective to the trigeminal system (Pardutz et 
al., 2000). NO might activate primary sensory fibres in the trigeminal system, since the 
depletion of neurotransmitter by capsaicin from these neurones abolishes this effect of NTG 
(Tassorelli et al., 1997).   
The alteration of c-Fos expression reflects the dose-dependent modulatory effect of 
KYNAa2 on the activation of second-order trigeminal neurones located in the C1-C2, which 
might be related to the inhibition of the peripheral nociceptors, but it may also arise central 
effects namely action on receptors located in the central part of the trigeminal system. 
Glutamatergic receptors can be detected on the second-order trigeminal neurones (Tallaksen-
Greene et al., 1992) and they are involved in nociceptive processing. Inhibition of these 
receptors can mitigate c-Fos increase in pain conditions (Mitsikostas et al., 1998; 1999). α7-
nACh receptors can be found on primary trigeminal nociceptors (Liu et al., 1998) and their 
inhibition by kynurenic acid may block glutamate release from the nerve endings (Carpenedo 
et al., 2001) and thus reduce the activation of secondary trigeminal neurones (Carstens et al., 
2000). 
Central action of KYNAa2 can be suggested in these experimental settings as well, since 
kynurenic acid and its derivatives administered intrathecally directly into the central nervous 
system can produce similar effects. Kynurenic acid significantly reduced the carrageenan-
induced c-Fos expression in laminae I-II and IV-V of ipsilateral spinal cord (Zhang et al., 
2003). 7-Chlorokynurenic acid significantly inhibited electrophysiological responses of 
convergent dorsal horn neurones in the second phase of formalin test (Chapman and 
Dickenson, 1995). Kynurenic acid and 7-chlorokynurenic acid demonstrated a dose-
dependent anti-nociceptive action in various animal models of nociception in mice and rats 
(Nasstrom et al., 1992; Kristensen et al., 1993) and anti-hyperalgesic effect in rats injected 
with carrageenan (Ren et al., 1992; Zhang et al., 2003). Similarly, 5,7-dichlorokynurenic acid 
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showed anti-hyperalgesic properties in Mg-deficient rats (Begon et al., 2001). Moreover, i.p. 
KYNAa1 was more effective mitigating c-Fos activation in the C1-C2 after NTG 
administration when compared to kynurenic acid alone probably due to its better blood-brain 
barrier penetrance (Knyihar-Csillik et al., 2008). 
KYNAa2, a derivative of kynurenic acid can attenuate the NTG-induced activation of 
second-order trigeminal neurones by direct or indirect (forming kynurenic acid) manner 
probably by acting both in the periphery and in the central nervous system.  
 
Sensitization of second-order trigeminal neurones 
nNOS is present in the dorsal horn neurones of the spinal cord suggesting a role in sensory 
and pain processing (Saito et al., 1994). NOS inhibitors block the activation of dorsal horn 
neurones after nociceptive stimuli (Wang et al., 1999) and can inhibit the trigeminovascular 
system (Akerman et al., 2002) and preliminary studies show that they might be effective 
treating migraine (Lassen et al., 1997) and tension type headache (Ashina, 2002). Previously, 
it was demonstrated that systemic NTG was able to enhance nNOS expression at the level of 
the C1-C2 (Pardutz et al., 2000) and similar changes were seen in the spinal cord after 
intradermal capsaicin administration (Wu et al., 2001) and in the TNC after facial formalin 
injections (Leong et al., 2000). In our experiments, NO derived from NTG might act via the 
stimulation of Aδ and C fibres of the primary trigeminal afferents (Pardutz et al., 2000). 
These observations suggest that NO donors may trigger a self-amplifying process at the level 
of central projection site of the trigeminal system by increasing endogenous NO synthesis, 
which might be relevant in migraine pathogenesis, where the central sensitization process is 
essential (Burstein et al., 2000). 
CaMKIIα is present in the superficial layers of the spinal dorsal horns (Fang et al., 2002). 
NTG increased CaMKIIα in the second-order neurones of the trigeminal system, which was 
also shown in previous studies (Pardutz et al., 2007). This phenomenon can be paralleled with 
the results showing increased expression of CaMKIIα in the spinal cord after subcutaneous 
formalin (Liang et al., 2004), capsaicin (Fang et al., 2002) and intrathecal substance-P (Choi 
et al., 2005) administration. Moreover CaMKIIα is able of autophosphorilation, which 
enhances its activity (Thiel et al., 1988). It can attach to NMDA receptors in rats and its alpha 
subunit enhances ion currents through AMPA and NMDA receptors (Kolaj et al., 1994) and 
activates adenylate cyclase related to spinal cord sensitization in animals (Wei et al., 2006). 
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L-KYN-PROB, KYNAa1 and KYNAa2 was able to inhibit the NTG-induced increase of 
nNOS and CaMKIIα expression at the level of second-order trigeminal neurones in the C1-
C2, which points to the attenuation of the central sensitization phenomena. Both nNOS and 
CaMKIIα seem to be key players in this process (Fang et al., 2002; Chacur et al., 2010), 
where neurones undergo plastic anatomical and functional changes involving the activation of 
AMPA and NMDA receptors (Latremoliere and Woolf, 2009) after strong noxious 
stimulation. Both AMPA and NMDA receptor blockers inhibit long term potentiation of the C 
fibre-mediated response in wide dynamic range neurones at the level of lumbar dorsal horn, 
which is thought to be related to central sensitization (Svendsen et al., 1998). LY235959 - a 
competitive NMDA antagonist - attenuated the behavioural responses of the second phase 
after formalin administration, which corresponds to the sensitization process (Davis and 
Inturrisi, 2001). Taken together, these results suggest that besides peripheral action, kynurenic 
acid derivatives may inhibit the increases of nNOS and CaMKIIα expression i.e. the NTG 
induced central sensitization through a possible blockade of AMPA and/or NMDA receptors. 
It can be also hypothesised that the inhibition of α7-nACh can play a role in the inhibition of 
the central sensitization process, since glutamate release can be lowered by antagonizing these 
receptors with kynurenic acid at the presynaptic level (Carpenedo et al., 2001).  
 
Behavioural effect of NTG 
NTG administration, which causes the activation and sensitization of the trigeminal system 
(Tassorelli and Joseph, 1995; Pardutz et al., 2000), significantly decreased the ambulation 
distance of the rats in the control group, which can be paralleled with other experiments, 
when pain conditions such as experimental spinal canal stenosis also reduced the ambulation 
distance (Li et al., 2013). On the other hand, NTG- and Placebo-treated subgroup did not 
show any significant difference of ambulation distance when pre-treated with KYNAa2 
suggesting an anti-nociceptive effect of the latter. Nonetheless, we found a tendency of lower 
basic ambulation distance in KYNAa2 pre-treated groups suggesting a direct central action of 
KYNAa2. This theory is also supported by findings that a glycine-site NMDA antagonist 
passing the blood-brain barrier can modulate the ambulation distance in the Open Field Test, 
while the antagonist with limited central access did not produce such effect (Christoph et al., 
2005).
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Conclusions 
 
In these experiments, we managed to manipulate the kynurenine system in rats either by 
increasing brain kynurenic acid levels by administrating L-KYN combined with PROB or 
injecting a newly synthesized kynurenic acid amide, which might act directly with a presumed 
similar receptorial action or can be metabolized to kynurenic acid and thus have an indirect 
mechanism of action. 
Kynurenic acid and its derivatives mitigated the NTG-induced trigeminal activation at the 
level of first- and second-order neurones. Moreover, they abolished changes related to the 
central sensitization process at the level of the C1-C2, where most of the trigeminal 
nociceptors are located. Since these events have a particular importance in the 
pathomechanism of headaches, kynurenic acid and its derivatives might have a potential role 
in the treatment of cephalalgias. 
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Értekezés tézisének magyar nyelvű összefoglalója 
 
Az elsődleges fejfájások közé tartozó migrén az egyik leggyakoribb neurológiai betegség, 
amelynek pontos patomechanizmusa nem ismert. A migrénes rohamok kialakulásában 
azonban alapvető a trigeminális rendszer aktiválódása és szenzitizációja, amelynek során az 
elsődleges trigeminális neuronok centrális és perifériás idegvégződéseiből 
neurotranszmitterek szabadulnak fel, mint például a glutamát vagy a kalcitonin gén-relációs 
peptid (CGRP). Következésképpen migrénesekben a roham alatt a vena jugularis externában 
emelkedett CGRP szint mérhető. A centrálisan felszabadult neuroaktív anyagok a másodlagos 
trigeminális neuronokat aktiválják, amelyek a nyúltvelőben lévő, de az első két cervikális 
gerincvelői szegmentumig lehúzódó nucleus tractus spinalis nervi trigemini pars caudalis 
(TNC) magban helyezkednek el. Az aktiválódás általánosan használt markere a c-Fos 
transzkripciós faktor. A perifériáról érkező folyamatos, hosszan tartó ingerlés hatására a 
másodlagos idegsejtekben létrejön a centrális szenzitizáció, amelyben a glutamát receptorok, 
a neuronális nitrogén-monoxid szintáz (nNOS) és a kalcium/kalmodulin-függő protein kináz 
II alfa (CaMKIIα) fontos szerepet játszanak. A centrális szenzitizáció a migrénes roham során 
az allodynia jelenségében nyilvánul meg, amely terápiás szempontból kritikus, hiszen 
kialakulása után jelentősen romlik a roham kezelhetősége.  
A nitrogén-monoxid (NO) donor nitroglicerin (NTG) szisztémás adása a migrén egyik 
humán és állatkísérletes modellje. A NTG általánosan ismert mellékhatása egy, a beadást 
követően azonnal kialakuló fejfájás, amelyet migrénesekben néhány óra elteltével egy típusos, 
aura nélküli migrénes roham követ, amelyet a migrén preventív és rohamterápiájában használt 
gyógyszerek képesek kivédeni vagy megszüntetni. Humán vizsgálatokban az NTG képes 
aktiválni és szenzitizálni a trigeminális rendszert és ez a jelenség állatkísérletes körülmények 
között is kimutatható: a TNC cervikális szakaszán (C1-C2) a NTG (i) csökkenti a CGRP-t 
tartalmazó rostok által lefedett területet, amely a transzmitter felszabadulást és az elsődleges 
trigeminális nociceptorok aktiválódását jelzi, (ii) növeli a c-Fos expressziót tükrözve a 
másodlagos trigeminális idegsejtek aktiválódását, valamint (iii) fokozza a nNOS és CaMKIIα 
immunreaktivitást, amelyek a centrális szenzitizációs folyamatok jelenlétére utalnak.  
A kinurénsav L-kinureninből (L-KYN) keletkezik az endogén triptofán metabolizmus 95%-
áért felelős kinurenin útvonal során. Kísérletes eredmények alapján a kinurénsav 
neuroprotektív és hatékony a fájdalomcsillapításban is, amely feltehetően annak köszönhető, 
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hogy képes gátolni a fájdalomérzés patomechanizmusában is fontos szerepet játszó ionotróp 
glutamát N-metil-D-aszpartát (NMDA) és α-amino-3-hidroxil-5-metil-4-izoxazol-propionát 
(AMPA), valamint az α7-nikotinos acetilkolin (α7-nACh) receptorokat, továbbá képes 
serkenteni a G-protein-kapcsolt-35 receptort (GPR-35). Terápiás alkalmazhatóságának 
viszont határt szab az, hogy csak kis mennyiségben képes átjutni a vér-agy gáton, ezért 
kísérletes körülmények között sokszor az L-KYN-t használják, amely önmagában nem 
neuroaktív vegyület, viszont könnyen átjut a vér-agy gáton és dózisfüggő módon képes 
megemelni a kinurénsav koncentrációját a központi idegrendszerben. Ez utóbbi jelentősen 
fokozható probeneciddel (PROB), amely a vér-agy gáton is jelenlévő és a kinurénsav 
központi idegrendszerből történő kiürüléséért is felelős szerves sav transzportereket gátolva 
éri el hatását. További lehetőséget jelent az olyan, újonnan szintetizált kinurénsav 
származékok használata, amelyek feltételezhetően jobban átjuthatnak a vér-agy gáton és 
megtartják a kiindulási vegyület biológiai hatásait, és/vagy a központi idegrendszerben 
visszaalakulnak kinurénsavvá.  
A fentiek alapján kísérleteink célja az volt, hogy PROB-el kombinált L-KYN-el és két 
újonnan szintetizált kinurénsav származékkal történt kezelést követően (i) megmérjük a 
kinurénsav koncentrációját a C1-C2-es régióban; (ii) megvizsgáljuk az esetleges moduláló 
hatásukat a NTG-indukálta trigeminális aktivációra és szenzitizációra; továbbá (iii) 
kimutassuk és moduláljuk a NTG kezelés állatok viselkedésére gyakorolt hatását.  
Az állatkísérleti irányelveket követő és a helyi hatóságok által engedélyezett kísérleteinkben 
felnőtt hím Sprague-Dawley patkányokat használtunk. A két új, oldallánc szubsztituált 
kinurénsav amidot a Szegedi Tudományegyetem Gyógyszerkémiai Intézetében szintetizálták 
(N-(2-N,N-dimetilaminoetil)-4-oxo-1H-quinolin-2-karboxamid hidroklorid - KYNAa1 és N-
(2-N-pirrolidiniletil)-4-oxo-1H-quinolin-2-karboxamid hidroklorid - KYNAa2). A C1-C2 
régió kinurénsav tartalmának meghatározásához intraperitoneális (i.p.) fiziológiás sóoldattal 
(n=4) vagy i.p. L-KYN (300 mg/testsúly kg (tskg)) és PROB (200 mg/tskg) kombinációjával 
(n=4) vagy i.p. KYNAa2-vel (1 mmol/tskg, n=2x5) kezeltük az állatokat. Meghatározott 
időpontokban (60 perc a kontroll és L-KYN-PROB csoportban; 60 és 300 perc a KYNAa2 
csoportban) az eltávolított C1-C2-es szegmentumok kinurénsav tartalmát nagy hatékonyságú 
folyadékkromatográfia (HPLC) segítségével mértük. A morfológiai vizsgálatokhoz a 
patkányokat i.p. fiziológiás sóoldattal (n=12) vagy i.p. L-KYN (300 mg/tskg) és PROB (200 
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mg/tskg) kombinációjával (n=12) vagy i.p. KYNAa1-el (1 mmol/tskg, n=12) vagy különböző 
dózisú i.p. KYNAa2-vel kezeltük (0,1, 0,5 és 1 mmol/tskg, n=10/csoport), amelyek után egy 
órával az állatok i.p. NTG-t (10 mg/tskg) vagy i.p. Placebo injekciót kaptak (n=5/6 
csoportonként). Négy óra elteltével a C1-C2-es régiót eltávolítottuk és CGRP, c-Fos, nNOS 
és CaMKIIα immunhisztokémiai festéseket végeztünk rajtuk. A C1-C2-es régió I-II 
laminájában a CGRP rostok által lefedett területet mértük és a c-Fos-, nNOS- és CaMKIIα-
immunreaktív (IR) neuronokat számoltuk. A Western blot analízishez a patkányokat i.p. 
fiziológiás sóoldattal (n=10) vagy i.p. KYNAa2-vel (1 mmol/tskg, n=10) kezeltük, amit egy 
óra elteltével i.p. NTG (10 mg/tskg) vagy i.p. Placebo injekció követett (n=5/csoport), majd 
négy órával ez után a C1-C2-es szegmentumokat eltávolítottuk és Western blot technika 
segítségével meghatároztuk a CGRP, nNOS és β-actin tartalmukat. Az Open Field Teszthez 
az állatok i.p. fiziológiás sóoldatot (n=20) vagy i.p. KYNAa2-t (1 mmol/tskg, n=20) kaptak, 
amit egy óra után i.p. NTG (10 mg/tskg) vagy i.p. Placebo injekció követett (n=10/csoport), 
majd három óra negyven perc elteltével 15 percig mértük a mozgással töltött időt, a megtett 
távolságot, a nyugalomban töltött időt és az ágaskodások számát.  
HPLC eredményeink alapján a kinurénsav koncentrációja egy órával az L-KYN-PROB 
kombinált kezelés után és a KYNAa2 kezelést követően is szignifikánsan megemelkedett a 
C1-C2-es régióban a kontroll csoporthoz viszonyítva, majd öt órával az utóbbi kezelés után 
visszacsökkent alap szintre. A C1-C2-es szakasz transzverzális metszetein a NTG 
szignifikánsan lecsökkentette a CGRP rostok által lefedett területet, és szignifikánsan 
megemelte a c-Fos-, nNOS- és CaMKIIα-IR sejtek számát a Placeboval kezelt állatokhoz 
képest, amelyet az L-KYN-PROB, KYNAa1 és dózisfüggő módon a KYNAa2 képes volt 
kivédeni. A Western blot mérésekből származó eredmények megerősítették az 
immunhisztokémiai adatokat, miszerint a CGRP mennyisége szignifikánsan csökkent és az 
nNOS mennyisége szignifikánsan nőtt a C1-C2-es szegmentumban NTG hatására a 
Placebohoz képest, amelyet a KYNAa2-vel történt előkezelés kivédett. Az Open Field 
Tesztben a NTG szignifikánsan lecsökkentette a patkányok által megtett távolságot a Placebo 
csoporttal összehasonlítva, míg ez a különbség a KYNAa2 előkezelést kapott állatoknál nem 
volt megfigyelhető.  
L-KYN-PROB kezelések hatására megfigyelhető jelentős kinurénsav emelkedés a C1-C2-es 
szegmentumban megerősíti a korábbi kísérleti eredményeket. A kinurénsav koncentrációjának 
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növekedése KYNAa2 kezelést követően a C1-C2-ben arra enged következtetni, hogy ez a 
származék legalább részben képes visszaalakulni a kiindulási vegyületté hasonlóan a 
KYNAa1-hez, amelyről kimutatták, hogy egér szérumban a kinurénsav koncentrációt is 
jelentősen megemeli. Mindezek alapján feltételezhetjük, hogy ezen származékok központi 
idegrendszeri hatásai részben direkt módon hatva és részben indirekt módon, visszaalakulva 
kinurénsavvá valósulnak meg.  
A migrén patomechanizmusának egyik főszereplője a CGRP, amelynek NTG-indukálta 
csökkenése a C1-C2-es régióban az elsődleges trigeminális neuronokból történő transzmitter 
felszabadulást és egyben ezen idegsejtek aktiválódását jelzi, amely korábbi kísérletek alapján 
specifikus a trigeminális rendszerre. Ezek az adatok összhangban vannak más eredményekkel, 
amelyek szerint a trigeminális rendszer aktiválódása CGRP felszabadulással jár a perifériás és 
a centrális nyúlványokból és ennek következtében a migrénes roham során emelkedett CGRP 
szint mérhető. Mivel az L-KYN-PROB, KYNAa1 és dózisfüggő módon a KYNAa2 képes 
volt kivédeni a NTG-indukálta CGRP csökkenést, feltételezhetjük, hogy ez a hatás a 
fájdalomérzésben fontos szerepet játszó, és a perifériás trigeminális rendszerben jelen lévő 
glutamát és α7-nACh receptorok gátlása vagy a GPR-35 receptorok serkentése révén 
valósulhat meg, amely hatások bizonyítottan képesek csökkenteni a CGRP felszabadulást 
vagy annak következményeit vagy modulálni a nociceptív jelátvitelt.  
A másodlagos trigeminális neuronok NTG-indukált aktiválódását jelzi a C1-C2 felszíni 
rétegeiben megfigyelt c-Fos immunreaktivitás növekedés, ami korábbi vizsgálatok alapján 
szintén specifikus a trigeminális rendszerre és feltételezhetően az elsődleges trigeminális 
neuronok aktiválásán keresztül valósul meg. A c-Fos expresszió növekedését a KYNAa2-vel 
történt előkezelés dózisfüggő módon védte ki, amely egyrészt megvalósulhat a perifériás 
nociceptorok gátlása révén, de ugyanakkor központi idegrendszeri hatás is valószínűsíthető. 
Ez utóbbit alátámasztja az, hogy a glutamát és α7-nACh receptorok jelen vannak az agyban 
elhelyezkedő trigeminális területeken és gátlásukkal csökkenthető a c-Fos expresszió vagy a 
glutamát felszabadulás. Továbbá, a közvetlenül a központi idegrendszerbe juttatott kinurénsav 
és analógjai fájdalomcsillapító hatásúak, és a perifériásan adagolt kinurénsavval ellentétben a 
KYNAa1 képes volt csökkenteni a NTG-indukált c-Fos expressziót a C1-C2-ben.  
Irodalmi adatok alapján az önerősítő folyamatokban fontos szerepet játszó nNOS és 
CaMKIIα expressziójának emelkedése a C1-C2-ben a NTG hatására kialakuló és a migrén 
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patogenezisében is nagyon fontos szerepet játszó centrális szenzitizációs folyamatokat mutatja 
a trigeminális rendszerben, amely korábbi eredmények alapján szintén specifikus. Ezek a 
megfigyelések összhangban vannak azokkal az adatokkal, amelyek szerint fájdalmas stimulus 
hatására expressziójuk megemelkedik a másodlagos fájdalomérző neuronokban, és amelyek 
egyben azt is bizonyítják, hogy szerepük van a fájdalom idegrendszeri feldolgozásában a 
trigeminális rendszer területén is. A KYNAa2 dózisfüggő módon kivédte a NTG-indukált 
nNOS expresszió emelkedését és az L-KYN-PROB, KYNAa1 és szintén dózisfüggően a 
KYNAa2 csökkentette a CaMKIIα-IR sejtek számát, amely eredmények arra utalnak, hogy 
ezek az anyagok képesek kivédeni a centrális szenzitizációs folyamatokat, feltételezhetően 
főként az ionotróp glutamát receptorok gátlása révén. Az NMDA és AMPA receptorok 
alapvetőek a fájdalmas inger hatására kialakuló plasztikus anatómiai és funkcionális 
változások létrejöttében, amelyet az is bizonyít, hogy ezen receptorok gátlásával 
csökkenthetőek a centrális szenzitizációra utaló morfológiai és magatartásbeli változások. 
Ugyanakkor valószínűsíthető, hogy az előkezelések gátló hatásában a preszinaptikus α7-
nACh receptorok blokkolása is szerepet játszhat csökkentve a glutamát felszabadulását az 
idegvégződésekből.  
Az Open Field Teszt során a megtett távolságban NTG hatására megfigyelt csökkenés 
párhuzamba állítható más kísérletekkel, ahol a fájdalmas stimulus szintén csökkentette a 
megtett távolságot. Ez a csökkenés a KYNAa2 előkezelést követően nem jelent meg jelezve 
annak esetleges fájdalomcsillapító hatását. Érdekes módon, a megtett távolság alapszintje a 
KYNAa2-vel és Placeboval kezelt állatokban kismértékben mérséklődött, amely utalhat a 
kinurénsav származék közvetlen központi idegrendszeri hatására, amelyet alátámaszt az a 
megfigyelés is, hogy egy, a vér-agy gáton jól penetráló NMDA antagonista szintén 
csökkentette ezt a paramétert ellentétben egy nem jól penetráló antagonistával.   
Összefoglalva, az L-KYN-PROB és a két kinurénsav származékkal történt előkezelések 
hatékonyak a NTG-indukált perifériás és centrális trigeminális aktiváció és szenzitizáció 
csökkentésében, amely egyrészt annak köszönhető, hogy megemelik a kinurénsav 
koncentrációját a központi idegrendszerben vagy az utóbbiak direkt módon is hathatnak 
feltehetően a kiindulási vegyület támadáspontjain. Adataink újabb és szélesebb körű 
eredményekkel támasztják alá azt a korábbi felvetést, miszerint a kinurénsav vagy 
származékai potenciális gyógyszerjelöltként jöhetnek szóba a migrén kezelésében.  
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